Frequently Asked Questions
The market is segmented based on , By Type (Immunoglobulin G (IgG) such as Molecule and Non Immunoglobulin G (IgG) such as Molecule), Mechanism of Action (Bispecific Diabodies and Bispecific T-Cell Engager Antibodies), Application (Oncology, Autoimmune Disease and Others), Drugs (Blinatumomab, Catumaxomab, Duligotumab and Others), Route of Administration (Oral and Injectable), End-Users (Hospitals, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies and Retail Pharmacies) – Industry Trends and Forecast to 2030.
.
The Global Bispecific Antibody Market size was valued at USD 545.00 USD Million in 2022.
The Global Bispecific Antibody Market is projected to grow at a CAGR of 6.9% during the forecast period of 2023 to 2030.
The major players operating in the market include Adimab, Innovent Biologics, Affimed GmbH, Amgen, AstraZeneca, Xencor, Sanofi, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, Eli Lilly, Pieris Pharmaceuticals, Mereo BioPharma Group, Sobi, TG Therapeutics, Merus, MacroGenics, Genmab, Emergent BioSolutions, Alteogen, Astellas Pharma, Novartis, CELGENE CORPORATION.
The market report covers data from the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of the Middle East and Africa.
